


PROFOUND MEDICAL

Pioneering a new standard of care in the
treatment of prostate cancer



Disclaimer

Certain information in this presentation and oral statements made during this meeting are forward-looking and relate to Profound's anticipated financial position, business strategy, events and courses of action. Words or phrases such as "anticipate," "objective," "may," "will," "might," "should," "could," "can," "intend," "expect," "believe," "estimate," "predict," "potential," "plan," "is designed to," "continue" or similar expressions suggest future outcomes. Forward-looking statements include, among other things, statements about: our anticipated cash needs and our estimates regarding our capital requirements and our need for additional financing; our expectations regarding our expenses, sales and operations; our ability to anticipate the future needs of our customers; our future growth strategy and growth rate; our future intellectual property; and our anticipated trends and challenges in the markets in which we operate. Such statements reflect our current views with respect to future events and are based on assumptions and subject to significant risks and uncertainties. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements.

- Our actual results, performance or achievements could differ materially from those contemplated, expressed or implied in our statements as a result of various risk factors including, but not limited to, the following:
- our ability to demonstrate clinical trial data that is consistent with management expectations;
- our ability to achieve regulatory approvals within the expected time frames announced and expected;
- our ability to achieve market acceptance of our device;
- availability of reasonable levels of third party reimbursement to end users using our device;
- our ability to reach and maintain agreements with Magnetic Resonance Imaging (MRI) manufacturers on commercially reasonable terms in order to validate our device within the MRI environment;
- our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights;
- our ability to successfully define, design and release new products in a timely manner that meet our customers' needs;
- our ability to manage cash flow, foreign exchange risk and working capital;
- business, economic and capital market conditions;
- market conditions and the demand and pricing for our products;
- our relationships with our customers and business partners;
- our ability to attract, retain and motivate qualified personnel;
- our ability to maintain technological leadership and competition in our industry;
- our manufacturing supply chain, including pricing of goods and availability of adequate manufacturing capacity from our manufacturing suppliers;
- our ability to manage our growth; and
- fluctuation in our quarterly operating results.

Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this presentation by you or any of your representatives or for omissions from the information in this presentation.

What if?

What if you could treat localized prostate cancer in 2 hours

Minimally invasively

With real-time image guidance

As an outpatient

With the same or even better outcomes than surgery or radiation

What would you do?

Company Overview

- A Canadian medical device company focused on commercializing a new patented, minimally invasive treatment for localized prostate cancer, (**TULSA**) Transurethral **UL**traSound **A**blation technology
- Founded in 2008 with capital invested to date of \$15.0M
- Patents: 5 issued in the US (system, method)
 7 pending in the US
 6 pending foreign applications
- Headquarters: Toronto, 26 employees



Commercialization Plans


Europe, Dec 2015



Canada, Jan 2016



U.S., 2017



Leadership Team

Steven Plymale, CEO

- More than 20 years of experience in the medical device industry
- Led Excel-Tech (Xltek) to profitability within 12 months of assuming GM role, as well as completed four acquisitions
- Served in senior management roles at **CryoCath**, **Cedara**, **Claron** and **Bluehaven**

Shameze Rampertab, CFO

- More than 15 years of experience in life science public companies and capital markets
- Former CFO of **Intellipharma**, listed on the NASDAQ and TSX
- Former Analyst with Jennings Capital (now Mackie Research), Canaccord Capital (now Canaccord Genuity) and Sprott Securities (now Cormark Securities)

Ron Kurtz, VP Engineering

- 20 years + of experience in engineering management and design, primarily focused on medical device development
- Former VP of R&D at **Xltek**; over 16 years successfully developed, patented and commercialized broad portfolio of diagnostic neurology products
- Deep knowledge of product life cycle management

Goldy Singh, VP Quality and Regulatory Affairs

- 15 years of experience in Quality & Regulatory Affairs in the medical device industry for a number of companies
- Former Director of Quality and Regulatory Affairs at **Xltek**; secured 510(k) and CE Mark approvals
- Successfully launched products into the U.S., Canada and Europe


Prostate Cancer Incidence

One in 7 men will be diagnosed with prostate cancer in their lifetime



Incidence


Approximately 500,000 new cases diagnosed worldwide per year
with a US\$40 billion market



500,000 new patients/yr
850,000 procedures/yr
US\$40 billion market

Prostate Cancer Market (EU and US)

of Procedures




Total Market (US\$B): Surgery \$18.4, Radiation \$20.3,
HIFU \$0.9, Cryo \$0.7

■ Surgery ■ Radiation ■ HIFU ■ Cryo


The Problem

While survival rates are high, current therapies bring undesirable complication rates



Complication Rates

Profound's technology results in fewer significant complications



*Thompson (Chair) et al for AUA Prostate Cancer Clinical Guideline Update Panel (2007) Guideline for the management of clinically localized prostate cancer: 2007 update. The Journal of Urology 177(6): 2106-31

*PMI 12-month Phase 1 Trial, GCP-10102 Table 10.

Initial TULSA Clinical Trial Results

Initial results from the TULSA multi-jurisdictional clinical trial demonstrate strong potential for Profound's technology.

Initial safety outcomes:

30 patients treated

No serious adverse effects

- Mild retention
- Urinary tract infections


Mild conditions resolved quickly

All patients had planned overnight stay in hospital and were discharged next morning

The Profound Solution

Advantages:

- Safe, fast and accurate
- Millimeter accuracy ablates cancerous tissue while sparing nearby critical structures
- Outpatient procedure with single treatment and rapid recovery time
- Minimally-invasive (transurethral) approach using thermal ablation to heat the prostate from the inside-out
- Guided by real-time MR imaging with temperature (thermometry) feedback
- Technology compatible with all leading MRI platforms



System Components

Disposables

Ultrasound
Applicator



Endorectal
Cooling Device




Capital Equipment


Positioning
System



Cart




The Procedure



Proven Accuracy

Testing in prostates showed excellent agreement between MRI temperature measurements, histology and contrast-enhanced MRI



MR Thermometry

□ 0% cell kill, all tissues outside are normal

Histology


△ 100% cell kill, all tissues inside are killed

Contrast-Enhanced MRI

— Prostate
— Region of non-perfusion

TULSA vs. HIFU


	TULSA (Profound Solution)	HIFU (Competitor Solution)
Imaging	MRI-Guided	Ultrasound-Guided
Treatment	Planar	Focused
Location	Trans-urethral	Trans-rectal
Volume	<100cc	<40cc
Duration	~40 minutes	~3 hours
Pre-Treatment	None	TURP, ADT




Reduced Tissue Damage

Our preclinical study observed 83% of urethral tissue was preserved after treatment


Inside-out




Outside-in



Milestones and Commercialization




Path to Commercialization




Pivotal Trial Costs

Pivotal Trial cost is estimated at \$7,000,000



Commercial Launch in Europe

Logistics Headquarters - Netherlands
Operations Base - Germany



Current Status

- \$29,700,000 gross proceeds
- Private Placement closed April 30, 2015
- Syndicate led by GMP and included Cormark, Bloom Burton, Mackie
- Qualifying Transaction approximate closing May 21, 2015 with release of funds
- Trading on TSXV under “PRN” thereafter
- Jonathan Goodman to join Board of Directors

Capitalization

Transactions

Event	Gross Proceeds
Private Placement	\$24.0MM
Secured Loan	4.0MM
Mira IV Amalgamation	1.7MM
Total	\$29.7MM

Estimated Post-Money Post-QT Proforma Share Summary

Common Shares	39.4MM
Options	2.9MM
Broker Warrants	0.6MM
Total Fully Diluted Shares Outstanding	42.9MM

Estimated Post-Money Post-QT Proforma Fully Diluted Ownership

BDC	22.8%
Genesys	21.2%
Knight	7.1%